CHMP issued a positive opinion for Lifyorli combination therapy, the drug generated strong Q2 2026 revenue of $47.6 million in its first commercial quarter, and the company has multiple pipeline programs in development for additional indications including Cushing's syndrome with an FDA target action date in December 2026.
Company achieved early FDA approval for Lifyorli, raised full-year revenue guidance to $950M-$1.05B, and demonstrated strong market performance with 39% stock appreciation over the past year. The insider's retention of 130,000 stock options and pre-scheduled nature of the sale (planned 8 months prior) suggest confidence in the company's future despite near-term profitability challenges.
Company faced a significant 50.4% stock price decline following FDA rejection of its relacorilant drug application due to insufficient evidence of effectiveness. Class action lawsuit filed alleging securities fraud and unlawful business practices.
The company is accused of making materially false and misleading statements about relacorilant's clinical trial strength and regulatory approval prospects while concealing material FDA concerns. This represents alleged securities fraud that caused investor harm during the class period (October 31, 2024 - December 30, 2025).
The company faces a class action lawsuit for allegedly making false and misleading statements about its lead drug candidate's FDA approval prospects. The FDA's rejection of the NDA and the resulting 50.4% stock price decline indicate significant operational and legal challenges.
Company faces securities fraud allegations for allegedly concealing FDA warnings while publicly promoting drug approval prospects. FDA rejected lead drug candidate relacorilant, resulting in 50% stock price crash and $2.5 billion market capitalization loss in a single day.
Company is subject to a securities class action lawsuit alleging material misrepresentations regarding clinical trial data and FDA approval prospects for its relacorilant drug, resulting in investor losses.
The company is accused of making materially false or misleading statements about FDA interactions and relacorilant NDA approval expectations. The FDA allegedly had concerns about the adequacy of the effectiveness assessment program and warned of significant review issues, contradicting defendants' positive public statements.
Company faces securities fraud allegations for allegedly concealing FDA warnings about insufficient clinical data while publicly promoting drug approval prospects. FDA rejected lead drug candidate relacorilant, causing 50% stock price collapse and $2.5 billion market cap loss in a single day.
The company faces a class action lawsuit for allegedly making misleading statements about its lead drug candidate's FDA approval prospects. The FDA rejected the NDA citing insufficient evidence, and the stock price collapsed 50.4% upon disclosure, indicating significant investor losses and reputational damage.
The company is accused of making materially false or misleading statements about FDA interactions and NDA approval expectations for relacorilant, when the FDA had actually raised significant concerns about the drug's effectiveness assessment program. This alleged fraud resulted in investor losses and triggered a class action lawsuit.
Company faces securities class action alleging material misrepresentation regarding FDA communications about its lead drug candidate. Stock experienced a catastrophic 50% single-day decline following FDA rejection, and the lawsuit claims management knowingly misled investors about approval prospects despite private FDA warnings of insufficient clinical evidence.
Company is subject to shareholder class action lawsuit alleging materially false/misleading statements regarding clinical trials and drug approval odds for relacorilant, indicating potential fraud and investor losses.
The company is the subject of a securities class action lawsuit alleging that management made misleading statements about clinical trial data and FDA approval prospects for its relacorilant drug, while the FDA had raised concerns about the adequacy of clinical evidence. This represents material misrepresentation to investors.
The company is accused of making false and misleading statements to investors regarding the viability and FDA approval status of its product candidate relacorilant. The lawsuit alleges the company knew clinical data was inadequate for approval while publicly claiming the product was 'approaching approval,' resulting in investor losses when the truth was revealed.
The company is the subject of a securities class action lawsuit alleging material misrepresentation regarding clinical trial data and FDA approval prospects for a key drug candidate. Defendants allegedly made false statements about FDA confidence and drug approval timeline, resulting in investor damages.
The company faces securities fraud allegations for failing to disclose material information about FDA approval prospects for its lead drug candidate. The 50% stock price collapse and Complete Response Letter from the FDA indicate significant business setback and investor losses.
Company faces securities class action lawsuit for allegedly concealing FDA concerns about insufficient clinical data. FDA rejected lead drug candidate relacorilant, resulting in 50% stock price collapse and $2.5 billion market cap loss in a single day.
Company is accused of misrepresenting the strength of clinical trial data and FDA communications regarding relacorilant NDA approval. Defendants allegedly concealed known material risks of FDA rejection while publicly stating confidence in approval, resulting in investor damages.
The company is accused of making false and misleading statements about clinical trial data and FDA communications regarding its relacorilant drug. Defendants allegedly misrepresented the strength of clinical evidence and FDA approval prospects, causing investor losses when the truth was revealed.
FDA approval of Lifyorli represents a major milestone for the company, enabling commercialization of a drug in the high-demand cancer treatment segment. The stock gained nearly 9% on the news, and an analyst upgraded the recommendation. The author expresses bullish sentiment on the company's future prospects.
Company faces securities class action lawsuit for allegedly concealing FDA concerns about insufficient clinical data for lead drug candidate. FDA issued Complete Response Letter rejecting the drug application, resulting in 50% stock price collapse and $2.5 billion market capitalization loss in a single day.
The company faced an FDA rejection of its key drug application (relacorilant), resulting in a 50.42% stock price decline. Additionally, a securities fraud lawsuit alleges the company made materially false statements and failed to disclose material adverse information about FDA concerns regarding the drug's clinical development program.
The company faces a securities class action lawsuit for allegedly failing to disclose material information about its lead drug candidate. The FDA rejected the drug application, and the stock price dropped 50.4% in a single day, indicating severe loss of investor confidence and significant financial impact.
Company faces securities class action lawsuit for allegedly concealing FDA concerns about insufficient clinical data. FDA rejected lead drug candidate relacorilant, resulting in 50% stock price collapse and $2.5 billion market capitalization loss in a single day.
Company faces securities fraud allegations for misrepresenting FDA communications and clinical trial adequacy regarding its relacorilant drug. FDA rejected the NDA with a Complete Response Letter, and stock price declined 50.4% on the announcement, indicating significant investor losses and regulatory setback.
The company is the subject of a securities class action lawsuit alleging material misrepresentations regarding clinical trial data and FDA communications for its relacorilant drug. The lawsuit claims defendants made false statements about FDA confidence and drug approval prospects, resulting in investor damages.
The company is accused of making materially misleading statements about clinical trial data and FDA approval prospects for its relacorilant drug. The FDA's Complete Response Letter denying approval and the resulting 50.4% stock price decline on December 31, 2025, combined with the securities fraud allegations, indicate significant negative developments for the company.
The company is accused of making false and misleading statements about clinical trial data and FDA communications regarding its relacorilant drug candidate. Defendants allegedly misrepresented the strength of clinical evidence and FDA approval prospects, causing investor damages when the truth was revealed.
The company is the subject of a securities class action lawsuit alleging material misrepresentations regarding clinical trial data and FDA approval prospects for its key drug candidate relacorilant. The lawsuit claims defendants made false statements about FDA confidence and drug approval timeline while concealing known regulatory concerns, resulting in investor damages.
The company faced a 50% stock price decline following FDA rejection of its drug application, with additional double-digit losses after disclosure that the FDA had previously warned about significant review issues. This indicates serious regulatory setbacks and potential securities law violations under investigation.
The company is accused of making false and misleading statements to investors about its lead drug candidate's regulatory prospects while allegedly ignoring FDA warnings about inadequate clinical data. The resulting stock collapse of 50% and $3.6 billion market value loss, combined with the FDA's Complete Response Letter rejection, represents a significant negative development for the company and its investors.
Company faces class action lawsuit for allegedly misrepresenting clinical trial data and FDA communications regarding relacorilant drug approval. FDA issued a Complete Response Letter indicating insufficient evidence, causing a 50.4% stock price decline from $70.20 to $34.80 in a single day.
The company is accused of making false and misleading statements to investors about its drug candidate's regulatory prospects while allegedly concealing FDA warnings about inadequate clinical data. The resulting stock price collapse of 50.4% and $3.6 billion market value loss, combined with the FDA's Complete Response Letter rejection, represents a significant negative development for investors.
Alleged failure to disclose FDA concerns about relacorilant effectiveness trial design and expected significant review issues
Company allegedly made false representations about clinical trial data supporting relacorilant NDA. FDA issued a Complete Response Letter indicating insufficient evidence of efficacy, contradicting management's prior statements about approval confidence.
The company is accused of making materially false or misleading statements about FDA interactions and drug approval expectations. The FDA allegedly had significant concerns about the relacorilant NDA review, which contradicts management's positive public statements, indicating potential securities fraud and investor harm.
The company is accused of making false and misleading statements to investors regarding clinical trial data and FDA approval prospects for its relacorilant drug. The lawsuit alleges material misrepresentation about FDA communications and approval confidence, resulting in investor losses when the true details emerged.
Company faces securities litigation for allegedly misleading investors about FDA approval prospects for its lead drug candidate. Stock experienced a catastrophic 50% single-day decline following FDA rejection, resulting in $3.6 billion in market value loss. Allegations include concealing FDA warnings about inadequate clinical data while publicly expressing confidence in regulatory approval.
The company faces a class action lawsuit alleging securities fraud and misrepresentation regarding its lead drug candidate relacorilant. The FDA rejected the drug application, causing a 50%+ stock price decline. The lawsuit alleges Corcept concealed known FDA concerns about clinical evidence adequacy despite publicly representing the application was approaching approval with no concerns.
Articles that tag CORT but are mainly about other companies.
Mentioned as a top holding in both ETFs, indicating it is a significant component of both portfolios but no specific performance judgment is made.
Company is subject to class action lawsuit filed by Rosen Law Firm, indicating allegations of securities violations and investor harm during the specified class period.
Company is subject to securities class action lawsuit, indicating alleged securities violations and investor harm.
Stock gained 4.61%, outperforming broader market decline, listed among top gainers
Subject of a securities class action lawsuit filed by Rosen Law Firm, indicating alleged securities violations or misrepresentations to investors.
Company is defendant in securities class action filed by Rosen Law Firm; specific allegations not detailed in provided excerpt but lawsuit indicates securities fraud claims.
Subject of a securities class action lawsuit announced by Rosen Law Firm, indicating alleged investor harm and potential misrepresentations.
Subject of a securities class action lawsuit filed by Rosen Law Firm, indicating alleged investor harm and potential securities violations.
Company involved in securities fraud class action related to FDA approval issues with a 50% stock decline, indicating material misrepresentation to investors.
Stock fell 50% due to FDA approval issues. Securities fraud lawsuit filed against company and executives for allegedly failing to disclose material information regarding FDA approval problems.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
